Wednesday, 16 Jan 2019

You are here

Two Lupus Studies

In this session we were given new data on ustekinumab for SLE (abstract 6L). Ustekinumab is an IL12/23 agent already approved for use in psoriasis, psoriatic arthritis and Cohn’s disease. This abstract presented results from a Phase II trial in active SLE. The trial enrolled 102 active SLE patients who were randomised to ustekimumab or placebo (3:2 ratio) and followed for 24 weeks with the SRI-4 being used as the primary end-point.  At week 24, the primary end-point was achieved in 60% of ustekinumab and 31% of placebo patients (p=0.0046). The risk of a flare was also lower in the ustekinumab treated group (p=0.0078). Skin and joint disease activity improved more in the ustekinumab group in those with activity in these organs at baseline. There were no significant imbalances in serious adverse events between the groups. A Phase III trial is now in development. 

Of interest, an abstract (2609) on Tuesday reported a data driven approach to literature mining to aid in identifying new potential targets for SLE therapy and using an objective scoring system. This approach had previously assessed ustekinumab as a potential target of interest in SLE. The results of this Phase II trial are also therefore nice proof of concept data to support this approach. Abstract 2609 reporting the literature mining exercise has also identified an additional 25 potential drugs for repurposing in SLE.

Hopefully there will be more to come both from this agent and the others from this pipeline to help address the significant unmet need in SLE.  

Add new comment

More Like This

Early Predictive Factors for Scleroderma Renal Crisis

It has been historically said that risk factors for scleroderma renal crisis (SRC) includes include cold exposure, steroid use, dehydration, rapid progression of skin disease, tendon friction rubs, anti-RNA polymerase III antibodies and pregnancy.  A new study examines risk factor for SRC at the onset and diagnosis in systemic sclerosis patients. 

Best of 2018: Ustekinumab May be Effective in Lupus

Ronald F van Vollenhoven and colleagues have reported in Lancet that ustekinumab (UST), an interleukin-12 and -23 inhibitor, when added to usual therapy in systemic lupus erythematosus (SLE) patients, was shown to be superior to placebo at improving clinical efficacy and laboratory parameters after 6 months of therapy.

Nailfold Videocapillaroscopy in Dermatomyositis

A study of nailfold videocapillaroscopy (NVC) in patients with idiopathic inflammatory myopathies (IIMs) finds abnormalities in more than half of patients suggesting this could be a useful clinical tool in diagnosing and managing patients with IIM. 

TIF1-Ab in Dermatomyositis Linked to Higher Cancer Risk

Several epidemiological studies have reported that a diagnosis of DM or PM may be associated with increased cancer risk. The association appears stronger for DM than PM. Based on a meta-analysis, DM cancer risk is five times higher than in the general population and twice that compared with PM cancer risk. 

Genetic Diagnosis for Previously Undiagnosed Disorders

The NEJM has reported the NIH's Undiagnosed Diseases Network (UDN) study results of genetically identifying new diseases from prospectively followed persons with undiagnosed disorders. The UDN was formed in 2014 as a network of seven clinical sites, two sequencing cores, a coordinating center, central biorepository, a metabolomics core, and a model organisms screening center. It was established to apply a multidisciplinary model in the evaluation of the most challenging cases and to identify the biologic characteristics of newly discovered diseases.